| Nelly W Kvirikadze, MD | |
|
660 N Westmoreland Rd, Lake Forest, IL 60045-1659 | |
| (847) 234-5600 | |
| (847) 941-7902 |
| Full Name | Nelly W Kvirikadze |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 41 Years |
| Location | 660 N Westmoreland Rd, Lake Forest, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932291069 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 036114198 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northwestern Lake Forest Hospital | Lake forest, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northwestern Medical Faculty Foundation | 4587576814 | 3255 |
News Archive
Neurotrope, Inc. (OTCQB: NTRP) today announced that results from a new study, entitled, "PKCe Deficits in Alzheimer's Disease Brains and Skin Fibroblasts," published in the recent edition of the peer-reviewed Journal of Alzheimer's Disease and co-authored by Tapan K. Khan, Ph.D.; Abhik Sen, Ph.D.; Jarin Hongpaisan, Ph.D.; Chol S. Lim, Ph.D.; Thomas J. Nelson, Ph.D., and; Dr. Daniel L. Alkon, each of the Blanchette Rockefeller Neurosciences Institute (BRNI), provide further indication of the role that protein kinase C epsilon (PKCe) may play in the potential treatment of Alzheimer's disease (AD).
Celldex Therapeutics, Inc. today announced positive results from Phase 1 studies of CDX-1307 in patients with advanced epithelial cancers, including breast, colon, bladder and pancreatic cancer.
Resistance strength training reduces pain and increases function and treatment satisfaction in people with hand osteoarthritis, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Francisco.
A new appreciation of how cancer cells evolve could help scientists design better screening methods to catch cancer before it advances.
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
› Verified 9 days ago
| Entity Name | Northwestern Medical Faculty Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346235314 PECOS PAC ID: 4587576814 Enrollment ID: O20031105000541 |
News Archive
Neurotrope, Inc. (OTCQB: NTRP) today announced that results from a new study, entitled, "PKCe Deficits in Alzheimer's Disease Brains and Skin Fibroblasts," published in the recent edition of the peer-reviewed Journal of Alzheimer's Disease and co-authored by Tapan K. Khan, Ph.D.; Abhik Sen, Ph.D.; Jarin Hongpaisan, Ph.D.; Chol S. Lim, Ph.D.; Thomas J. Nelson, Ph.D., and; Dr. Daniel L. Alkon, each of the Blanchette Rockefeller Neurosciences Institute (BRNI), provide further indication of the role that protein kinase C epsilon (PKCe) may play in the potential treatment of Alzheimer's disease (AD).
Celldex Therapeutics, Inc. today announced positive results from Phase 1 studies of CDX-1307 in patients with advanced epithelial cancers, including breast, colon, bladder and pancreatic cancer.
Resistance strength training reduces pain and increases function and treatment satisfaction in people with hand osteoarthritis, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Francisco.
A new appreciation of how cancer cells evolve could help scientists design better screening methods to catch cancer before it advances.
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nelly W Kvirikadze, MD 680 N Lake Shore Dr, Suite 1000, Chicago, IL 60611-4546 Ph: () - | Nelly W Kvirikadze, MD 660 N Westmoreland Rd, Lake Forest, IL 60045-1659 Ph: (847) 234-5600 |
News Archive
Neurotrope, Inc. (OTCQB: NTRP) today announced that results from a new study, entitled, "PKCe Deficits in Alzheimer's Disease Brains and Skin Fibroblasts," published in the recent edition of the peer-reviewed Journal of Alzheimer's Disease and co-authored by Tapan K. Khan, Ph.D.; Abhik Sen, Ph.D.; Jarin Hongpaisan, Ph.D.; Chol S. Lim, Ph.D.; Thomas J. Nelson, Ph.D., and; Dr. Daniel L. Alkon, each of the Blanchette Rockefeller Neurosciences Institute (BRNI), provide further indication of the role that protein kinase C epsilon (PKCe) may play in the potential treatment of Alzheimer's disease (AD).
Celldex Therapeutics, Inc. today announced positive results from Phase 1 studies of CDX-1307 in patients with advanced epithelial cancers, including breast, colon, bladder and pancreatic cancer.
Resistance strength training reduces pain and increases function and treatment satisfaction in people with hand osteoarthritis, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Francisco.
A new appreciation of how cancer cells evolve could help scientists design better screening methods to catch cancer before it advances.
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
› Verified 9 days ago
Dr. Mohamed Moatez Bayoumi, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1000 N Westmoreland Rd, Lake Forest, IL 60045 Phone: 847-234-5600 Fax: 847-535-7203 | |
Cheong M Yu, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1000 N Westmoreland Rd, Lake Forest, IL 60045 Phone: 847-234-5600 Fax: 847-535-7203 | |
Lillian Soong, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 660 N Westmoreland Rd, Lake Forest, IL 60045 Phone: 847-234-5600 | |
Dr. Thomas Alexander Morrison, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 660 N Westmoreland Rd, Lake Forest, IL 60045 Phone: 847-535-7181 | |
Safeer Shah, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 1000 N Westmoreland Rd, Lake Forest, IL 60045 Phone: 847-234-5600 Fax: 847-535-7203 | |
Marissa Jane Versalle, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1000 N Westmoreland Rd, Lake Forest, IL 60045 Phone: 847-234-5600 Fax: 847-535-7203 | |
Michael Belmont, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1000 N Westmoreland Rd, Lake Forest, IL 60045 Phone: 847-234-5600 Fax: 847-535-7203 |